Drugs limiting excess mucus could save lives

Respiratory conditions that restrict breathing such as asthma and chronic obstructive pulmonary disease are common killers worldwide. But no effective treatments exist to address the major cause of death in these conditions – excess mucus production. Now, researchers at Washington University School of Medicine in St. Louis have described the molecular pathway responsible for excess mucus in airway cells and have used that information to design a series of new drugs that inhibit that pathway. Specifically, Michael Holtzman, M.D., and his colleagues designed drugs (yellow) that bind with the MAPK13 enzyme (grey) to limit excess mucus production in airway cells. According to Holtzman, the drugs could help patients with life-threatening respiratory conditions including COPD and asthma. Credit: Michael J. Holtzman, M.D.

Respiratory conditions that restrict breathing such as asthma and chronic obstructive pulmonary disease (COPD) are common killers worldwide. But no effective treatments exist to address the major cause of death in these conditions – excess mucus production.

"There is good evidence that what kills people with severe or asthma is mucus obstructing the airway," says Michael J. Holtzman, MD, the Selma and Herman Seldin Professor of Medicine at Washington University School of Medicine in St. Louis. "It's a huge unmet medical problem and is only increasing in this country and throughout the world."

Now, Holtzman and his colleagues have described the molecular pathway responsible for excess mucus in and have used that information to design a series of that inhibit that pathway.

Their study appears online Nov. 26 in the .

Chronic respiratory disease, especially COPD, is the third leading cause of death in the United States and worldwide. Smoking and exposure to pollution are major causes of these diseases. Related conditions that affect the respiratory airways, like asthma and bronchitis, are also among the most common causes of human disease in adults and children. The morbidity and mortality from these conditions is closely linked to excess that blocks the airways and prevents normal breathing. However, there are no effective treatments to address the overproduction of airway mucus.

As part of the new research, the scientists discovered that a critical signaling molecule, CLCA1, has a special role in the mucus pathway. They showed that CLCA1 allows a protein known as IL-13 to turn on the major mucus gene in airway cells. The researchers also showed that CLCA1 needs help from an enzyme called MAPK13.

This video is not supported by your browser at this time.
Respiratory conditions that restrict breathing such as asthma and chronic obstructive pulmonary disease are common killers worldwide. But no effective treatments exist to address the major cause of death in these conditions – excess mucus production. Now, researchers at Washington University School of Medicine in St. Louis have described the molecular pathway responsible for excess mucus in airway cells and have used that information to design a series of new drugs that inhibit that pathway. Credit: Washington University School of Medicine in St. Louis

Although there were no existing drugs that acted against MAPK13, Holtzman says there were several that inhibit a similar enzyme known as MAPK14, which differs slightly in structure.

"We could take advantage of the MAPK14 inhibitors that were already known," Holtzman says. "These drugs bind to a specific pocket in MAPK14 to block its activity. For MAPK13, that pocket itself has some obstructions making it more crowded and harder to access, so these older drugs can't fit into the pocket to block activity."

So Holtzman and his team built drugs with slimmer structures that could avoid the obstacles and better fit into the protein pocket of MAPK13.

"We sculpted the drugs so they're better able to bind in the MAPK13 pocket," Holtzman says. "And we showed that the new shape translates into more potent and effective blockade of MAPK13 activity. It's drug discovery that takes advantage of biology and chemistry, and it takes a very special team to do that."

Indeed, the results show that some of their newly designed MAPK13 inhibitors reduced mucus production in cultures of human airway cells by 100 fold.

Importantly, Holtzman says that this work had to be done in human cells because commonly used lab animals have different wiring for the mucus production circuit. For example, MAPK13 inhibitors were not effective in mice because other types of CLCA and MAPK proteins could continue to make excess mucus.

"We recognized that we had to work directly in human cells to figure out the control system," Holtzman says. "We then looked at lungs from patients with very severe COPD who were at the last resort of lung transplantation. In these diseased lungs, we found too much mucus, too much CLCA1 and over-activated MAPK13. What we observed in isolated translated to a devastating disease in real life."

Beyond COPD and asthma, Holtzman also sees a possible role for MAPK13 inhibitors in related conditions with excess mucus production, like cystic fibrosis and even the common cold.

"The big killer is COPD," Holtzman says. "But other extra-mucus conditions can also be life threatening. And we know from our studies that respiratory viral infections and allergies are potent activators of this same pathway for mucus production. Since the new inhibitors would be active in both the upper and lower airways, they could impact a wide set of respiratory illnesses."

More information: Alevy YG, Patel AC, Romero AG, Patel DA, Tucker J, Roswit WT, Miller CA, Heier RF, Byers DE, Brett TJ, Holtzman MJ. IL-13 induced airway mucus production is attenuated by MAPK13 inhibition. Journal of Clinical Investigation. Online Nov. 26, 2012.

Related Stories

New airway stem cell found

Jun 27, 2011

Researchers at UCLA have identified a new stem cell that participates in the repair of the large airways of the lungs, which play a vital role in protecting the body from infectious agents and toxins in the environment.

Personalized therapy for asthma and COPD could soon be here

May 18, 2008

Researchers at Washington University School of Medicine in St. Louis have defined a new type of immune response that is activated in patients with severe asthma and COPD (chronic obstructive pulmonary disease). Their discovery ...

Discovery could lead to new therapies for asthma, COPD

Jan 27, 2011

Researchers have proved that a single "master switch" enzyme, known as aldose reductase, is key in producing excess mucous that clogs the airways of people with asthma and chronic obstructive pulmonary disease (COPD). The ...

New proteins to clear the airways in cystic fibrosis and COPD

Jul 13, 2012

University of North Carolina scientists have uncovered a new strategy that may one day help people with cystic fibrosis and chronic obstructive pulmonary disorder better clear the thick and sticky mucus that clogs their lungs ...

Recommended for you

Test shows Spain nursing assistant clear of Ebola

7 hours ago

A Spanish nursing assistant appears to have recovered from the Ebola virus, authorities said Sunday, nearly two weeks after she became the first person infected outside West Africa in the current outbreak.

Nigeria expected to be declared Ebola-free

18 hours ago

Nigeria is expected to be declared Ebola-free on Monday, just three months after fears that the virus could spread like wildfire through Africa's most populous nation.

User comments